Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management
Authors
Keywords
-
Journal
Hormones-International Journal of Endocrinology and Metabolism
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-09-27
DOI
10.1007/s42000-023-00491-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration
- (2022) Tomonori Kobayakawa et al. Modern Rheumatology
- Correction: UK clinical guideline for the prevention and treatment of osteoporosis
- (2022) Celia L. Gregson et al. Archives of Osteoporosis
- Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease
- (2022) Edgar Wiebe et al. ANNALS OF THE RHEUMATIC DISEASES
- The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials
- (2022) Zhi-Ming Liu et al. PLoS One
- Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club
- (2022) Michaël R. Laurent et al. Frontiers in Endocrinology
- Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures
- (2021) Alexander Egeberg et al. JAMA Dermatology
- Topical Corticosteroids and Glucocorticoid-Induced Osteoporosis—Cumulative Dose and Duration Matter
- (2021) Rebecca D. Jackson JAMA Dermatology
- Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
- (2021) Athanasios D. Anastasilakis et al. Journal of Clinical Medicine
- Clinical Utility of Trabecular Bone Score (TBS) in Fracture Risk Assessment of Patients with Rheumatic Diseases Treated with Glucocorticoids
- (2021) Anna Nowakowska-Płaza et al. HORMONE AND METABOLIC RESEARCH
- Validation of the Surrogate Threshold Effect for Change in BMD as a Surrogate Endpoint for Fracture Outcomes: the FNIH‐ASBMR SABRE Project
- (2021) Richard Eastell et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice
- (2021) Mikkel Bo Brent et al. Scientific Reports
- Understanding and Managing Corticosteroid-Induced Osteoporosis
- (2021) Alexandra O Kobza et al. Open Access Rheumatology-Research and Reviews
- Glucocorticoid-induced osteoporosis: Insights for the clinician
- (2020) Shakaib Hayat et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS
- (2020) Elena Tsourdi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucocorticoid-induced osteoporosis: 2019 concise clinical review
- (2019) G. Adami et al. OSTEOPOROSIS INTERNATIONAL
- Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia
- (2019) H. Chandler et al. OSTEOPOROSIS INTERNATIONAL
- Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society
- (2019) Athanasios D. Anastasilakis et al. BONE
- Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study
- (2018) Kenneth G Saag et al. Lancet Diabetes & Endocrinology
- Glucocorticoid-Induced Osteoporosis
- (2018) Lenore Buckley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
- (2017) Athanasios D Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy
- (2017) C.-C. Chi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Differentiation of Bone Marrow Mesenchymal Stem Cells in Osteoblasts and Adipocytes and its Role in Treatment of Osteoporosis
- (2016) Cheng Wang et al. MEDICAL SCIENCE MONITOR
- Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis
- (2015) Benjamin Z. Leder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials
- (2015) M. A. Amiche et al. OSTEOPOROSIS INTERNATIONAL
- Meta-Review: Adverse Effects of Inhaled Corticosteroids Relevant to Older Patients
- (2014) Katharina Mattishent et al. DRUGS
- Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions
- (2013) Irene EM Bultink et al. EXPERT OPINION ON PHARMACOTHERAPY
- Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial
- (2013) Claus-C Glüer et al. JOURNAL OF BONE AND MINERAL RESEARCH
- A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis
- (2012) S. Lekamwasam et al. OSTEOPOROSIS INTERNATIONAL
- Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis
- (2011) Banu B. Kalpakcioglu et al. BONE
- Guidance for the adjustment of FRAX according to the dose of glucocorticoids
- (2011) J. A. Kanis et al. OSTEOPOROSIS INTERNATIONAL
- Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial
- (2010) C. C. Mok et al. ANNALS OF THE RHEUMATIC DISEASES
- Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity
- (2009) Robert S. Weinstein BONE
- Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis
- (2009) J.-P. DEVOGELAER et al. JOURNAL OF RHEUMATOLOGY
- Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
- (2009) David M Reid et al. LANCET
- Mechanisms of glucocorticoid-induced myopathy
- (2008) O Schakman et al. JOURNAL OF ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now